About
Endoscopic Ultrasound (EUS) is one of the most advanced GI tools, essential for both diagnosis and minimally invasive procedures such as RFA, localized radiation therapy, and non-surgical drainage. However, its potential is limited by the years of expertise needed to perform these procedures safely and accurately. This makes EUS an ideal candidate for Human-AI collaboration, as it will enable more GI clinics to offer advanced treatments to more patients world-wide.
Our patent-pending AI, developed at Clalit, excels at detecting pancreatic abnormalities and shows promising results in malignancy classification. Multiple clinical trial sites are already in place.
Our founding team—experts in tech, AI, and clinical care—is driven to make advanced cancer treatments more accessible and effective for patients worldwide.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is EUSense's primary focus?
- EUSense focuses on transforming GI cancer diagnosis and treatment using AI for endoscopic ultrasound.
- When was EUSense founded?
- EUSense was founded in July 2024.
- What is the current operational status of EUSense?
- EUSense is currently inactive and ceased to operate in December 2025.
- Where is EUSense headquartered?
- EUSense is headquartered in Jerusalem, Israel.
- What is the current funding stage of EUSense?
- EUSense is in the Pre-Funding stage, with a total raised amount of $0 USD.
- What is EUSense's employee count?
- EUSense has 2 employees.
- What technology is EUSense utilizing in its solutions?
- EUSense utilizes Artificial Intelligence, Deep Learning, Computer Vision, and Image Recognition technologies.
- Has EUSense developed any patented technology?
- Yes, EUSense has a patent-pending AI technology developed at Clalit.